Group 1 - The core viewpoint of the news is that Changshan Pharmaceutical experienced a stock price increase of 5.22%, reaching 46.80 CNY per share, with a trading volume of 677 million CNY and a turnover rate of 1.62%, resulting in a total market capitalization of 43.012 billion CNY [1] - Changshan Pharmaceutical, established on September 28, 2000, and listed on August 19, 2011, is primarily engaged in the research, production, and sales of heparin series products [1] - The company's main business revenue composition includes 47.47% from water injection preparations, 39.24% from heparin raw materials, and 13.29% from other products [1] Group 2 - From the perspective of fund holdings, one fund under Bosera Fund has a significant position in Changshan Pharmaceutical, with the Bosera National Index 2000 ETF holding 1,400 shares, accounting for 0.55% of the fund's net value, ranking as the fifth-largest holding [2] - The Bosera National Index 2000 ETF, established on November 23, 2023, has a latest scale of 11.7815 million CNY and has achieved a year-to-date return of 38.28%, ranking 1165 out of 4220 in its category [2] - The fund manager, Tang Yibing, has a cumulative tenure of 3 years and 66 days, with the fund's total asset scale at 9.874 billion CNY, achieving the best return of 83.84% and the worst return of -41.93% during his tenure [2]

Group 1 - The core viewpoint of the news is that Changshan Pharmaceutical has shown significant trading activity and financial metrics, indicating a high level of investor interest and potential volatility in its stock performance [1][2]. - On September 11, Changshan Pharmaceutical's stock rose by 3.42%, with a trading volume of 1.446 billion yuan. The net financing purchase on that day was 14.843 million yuan, with a total financing and securities balance of 2.027 billion yuan, which is 4.50% of its market capitalization [1]. - The company has a high financing balance, exceeding the 90th percentile of the past year, indicating strong investor engagement. The securities lending balance is also at a high level, with a remaining quantity of 100 shares and a balance of 4,898 yuan [1]. Group 2 - As of September 10, the number of shareholders for Changshan Pharmaceutical was 48,100, a decrease of 2.90% from the previous period. The average circulating shares per person increased by 2.99% to 19,079 shares [2]. - For the first half of 2025, Changshan Pharmaceutical reported a revenue of 492 million yuan, a year-on-year decrease of 13.42%. However, the net profit attributable to the parent company was -29.089 million yuan, showing a year-on-year increase of 37.98% [2]. - Since its A-share listing, Changshan Pharmaceutical has distributed a total of 181 million yuan in dividends, with 4.5953 million yuan distributed over the past three years. As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth-largest circulating shareholder, increasing its holdings by 8.0391 million shares [3].